Sham-controlled RCT in 83 patients with type IIIB chronic prostatitis/chronic pelvic pain syndrome: four weekly low-intensity shock wave sessions with the P100 device gave a higher week-4 response rate than sham (78.4% vs 25%; P<0.001). No treatment-related adverse events.
RCTn = 83 patients
Zhang et al. Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial